Question-and-Answer SessionI guess I'd like to kick things off just with a high-level overview of your company, the beauty industry at large. It's really seen an increase in online penetration over the last few years. So could you talk us through your time as CFO and what you've done really to be able to operate in the beauty DTC industry in a way that really others haven't.Lindsay MannGlobal Chief Financial Officer Yes. Thanks for having me. ODDITY today is, we believe, the largest direct-to-consumer beaut ...

Group 1 - The session is part of the Global Credit Bureau Forum, featuring presentations from Experian's senior business leaders and showcasing their products [1] - The agenda includes an overview from the Group CFO, followed by presentations on North America Consumer Services, U.K. Consumer Services, and Brazil Consumer Services [2] - The session will conclude with a Q&A involving the senior leadership team, allowing for audience interaction [3]

Question-and-Answer SessionSo ODDITY is a unique company that prides itself on doing things differently. Since some of our audience may not be as familiar with the company, could you just give us an overview of ODDITY and what makes it different than traditional DT or tech companies?Lindsay MannGlobal Chief Financial Officer Yes. Thanks for having me. So I think there's so many things that make ODDITY different. But the first thing I would call out is truly culture of innovation, moving fast, failing fast, ...

Core Viewpoint - The article discusses the investment potential of ODD, highlighting the author's positive outlook based on personal investment positions and analysis [1]. Group 1 - The author holds a beneficial long position in ODD shares, indicating confidence in the company's future performance [1]. - The article expresses personal opinions and analysis without external compensation, suggesting an independent viewpoint [1]. - There is no business relationship with any company mentioned, reinforcing the objectivity of the analysis [1]. Group 2 - The article does not provide specific financial data or performance metrics related to ODD or the broader industry [2]. - No recommendations or advice are given regarding investment suitability, emphasizing a neutral stance on investment decisions [2]. - The authorship includes both professional and individual investors, indicating a diverse range of perspectives in the analysis [2].

Core Insights - ODDITY Tech Ltd. reported strong Q2 2025 results, with net sales and earnings exceeding estimates and showing year-over-year growth [1][3] - The company raised its full-year outlook, driven by robust top-line growth and strategic investments in innovation [2] Financial Performance - Adjusted EPS for Q2 was 92 cents, beating the estimate of 88 cents, and increased by 12.2% year-over-year [3] - Net sales reached $241.1 million, surpassing the estimate of $239 million, and grew by 25.1% from $192.8 million in the prior year [3] - Online DTC sales rose by 29.6% to $235.2 million, constituting 98% of total sales, up from 94% in the previous year [4] Margin and Cost Analysis - Gross profit was $174.4 million, a 25.3% increase from $139.1 million last year, with a gross margin of 72.3% [5] - SG&A expenses increased by 36.3% to $117.3 million, representing 48.6% of net sales, up 200 basis points year-over-year [5] - Operating income was $57.1 million, a 7.6% increase, while the operating margin declined to 23.7% [6] Strategic Developments - ODDITY's core brands, IL MAKIAGE and SpoiledChild, achieved double-digit online sales growth, supported by AI-driven personalization [10] - The company is on track to launch Brand 3 in Q4 2025, targeting the medical-grade dermatology segment, and Brand 4 is expected to launch in 2026 [11] - ODDITY raised $600 million through its first exchangeable note offering, indicating strong investor confidence [12] Future Guidance - For FY25, ODDITY expects net sales between $799 million and $804 million, reflecting 23-24% year-over-year growth [13] - Adjusted EBITDA is projected between $160 million and $162 million, with adjusted EPS expected between $2.06 and $2.09 [14] - For Q3 2025, net sales are anticipated to be between $144 million and $146 million, indicating year-over-year growth of 21-23% [14] Financial Health - As of June 30, 2025, ODDITY had cash and cash equivalents of $656.8 million, no long-term debt, and shareholders' equity of $351.2 million [9]

Financial Data and Key Metrics Changes - In Q2 2025, the company achieved a revenue growth of 26% to $509 million, generated adjusted EBITDA of $122 million, and free cash flow of $99 million, surpassing the entire free cash flow delivered in 2023 [4][30] - The adjusted diluted earnings per share for Q2 was $0.92, exceeding the guidance of $0.85 to $0.89 [29] - Gross margin expanded to 72.3%, exceeding guidance of 70.5% [28] Business Line Data and Key Metrics Changes - The company reported double-digit online growth in both its brands, Il Makiage and Spoiled Child, with Il Makiage expected to reach $1 billion in revenue by 2028 [12][24] - Spoiled Child is projected to cross $200 million in revenue this year, having launched only three years ago [13][42] Market Data and Key Metrics Changes - International sales represented approximately 15% of total net revenue, with a growth of over 40% in the first half of 2025, amounting to around $85 million [25][62] - The company is focusing on expanding its international presence, particularly in markets like the UK, Germany, Canada, Australia, and Israel, where it aims to replicate its U.S. success [27][62] Company Strategy and Development Direction - The company aims to become one of the largest beauty companies globally, with a focus on expanding its product offerings into healthcare, starting with dermatology [5][15] - Investments are being made in technology and new brands, with a strong emphasis on innovation and consumer demand for high-efficacy products [8][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another record-breaking year in 2025, with expected net revenue between $799 million and $804 million, representing a year-over-year growth of 23% to 24% [32] - The company plans to front-load investments in 2026, which may impact EBITDA margins in the first half of the year but is expected to maintain a long-term growth algorithm of 20% revenue growth and 20% adjusted EBITDA margin [34] Other Important Information - The company successfully issued its first convertible exchangeable note, upsized to $600 million, which significantly increased its cash position to $815 million [31] - The company is preparing for the launch of Brand Three, which will enter the medical-grade space, focusing on dermatology and offering both OTC and prescription products [13][15] Q&A Session Summary Question: What is driving the sequential compression in gross margin for Q3? - Management explained that gross margin is not a primary metric managed by teams, who focus on contribution margin, and that seasonality and lower revenue dollars in Q3 and Q4 contribute to the compression [39][40] Question: Will the company constrain growth on existing brands to manage future growth? - Management confirmed that they often constrain growth to ensure sustainable long-term growth, maintaining a commitment to 20% revenue growth and 20% adjusted EBITDA margin [51][52] Question: What are the investment plans for Brand Three and expected returns? - Management indicated that significant investments are being made in new brands and technology, with expectations of substantial future returns similar to past successful launches [56][57] Question: What are the growth drivers for international markets? - Management highlighted that international markets could be as large as the U.S. business, with strong growth in established markets and potential in new testing markets [62] Question: How will the go-to-market strategy differ for Brand Three? - Management stated that while the strategy will leverage existing technology and user base, it will also incorporate personalized treatments developed over two years [71][72] Question: What long-term revenue streams are anticipated from Brand Three? - Management outlined that Brand Three will operate as a telehealth platform with medical-grade products, focusing on compliance and leveraging existing user data for product development [78][80]

Financial Data and Key Metrics Changes - In Q2 2025, the company achieved a revenue growth of 26% to $509 million, generated adjusted EBITDA of $122 million, and free cash flow of $99 million, surpassing the entire free cash flow delivered in 2023 [5][25][32] - The adjusted EBITDA margin for Q2 was 28.8%, which compressed by approximately 350 basis points due to planned growth investments [31] - The gross margin expanded by 10 basis points year over year to 72.3%, exceeding guidance of 70.5% [30] Business Line Data and Key Metrics Changes - The company reported double-digit online growth in both its brands, Il Makiage and Spoiled Child, contributing to the overall revenue increase [26][10] - Il Makiage is on track to reach $1 billion in revenue by 2028, with international sales representing 15% of the business in 2024 [13][29] - Spoiled Child is projected to cross $200 million in revenue this year, having launched only three years ago [14] Market Data and Key Metrics Changes - International sales grew over 40% in the first half of 2025, amounting to approximately $85 million, with $75 million from established markets and $10 million from new testing markets [66] - The company is focusing on expanding its presence in international markets, which currently represent a smaller portion of its overall revenue compared to competitors [29][66] Company Strategy and Development Direction - The company aims to become one of the largest beauty companies globally, with a focus on expanding its online presence and entering the healthcare market [6][7] - Upcoming launches include Brand three, which will focus on medical-grade dermatology products, and Brand four next year [14][35] - Investments in technology and new brands are prioritized to sustain long-term growth and innovation [12][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 20% revenue growth and 20% adjusted EBITDA margin in the long term, even without contributions from new brands [34][44] - The company is preparing for a strong finish to 2025, driven by a backlog of repeat sales and a focus on long-term initiatives [11][34] Other Important Information - The company generated $99 million in free cash flow in the first half of 2025, converting over 80% of adjusted EBITDA into free cash [32] - The company has a remaining buyback authorization of $103 million with no share repurchases year to date [33] Q&A Session Summary Question: What is driving the sequential compression in gross margin for Q3? - Management explained that gross margin is not a primary metric they manage to, and seasonal factors contribute to lower margins in the second half of the year due to repeat business dynamics [40][42] Question: Will Brand three's success impact growth management for existing brands? - Management confirmed that they do not need Brand three for their 2025 or 2026 outlook, as existing brands have sufficient growth potential [44][45] Question: What is the strategy for Brand three's launch? - Management indicated that a soft launch will occur in Q3 to test the market, with a full launch planned for Q4 [52] Question: What are the growth drivers for international markets? - Management highlighted that international markets are expected to grow significantly, with a focus on deeper penetration and new market entries [63][66] Question: How does Brand three differ from previous launches? - Management noted that Brand three will leverage advanced technology and personalized treatment plans, setting it apart from traditional offerings [72][74]

the concentration of our voling power as a result of our dual class structure; our status as a foreign private issuer, and other risk factors set forth in the section titled "Risk Fadors" in the Company's Amud Recort on Form 20-F filed with the Sexrities Exchange Commission (the "SEC") on February 25, 2025 and other documents filed or furrished to the SEC. These statements reflect management's current expectations regading fulure events and operating performance and speak only as of the date of this press r ...

Core Viewpoint - Oddity Tech reported quarterly earnings of $0.92 per share, exceeding the Zacks Consensus Estimate of $0.88 per share, and showing an increase from $0.82 per share a year ago, indicating a positive earnings surprise of +4.55% [1] Financial Performance - The company achieved revenues of $241.14 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.83% and reflecting a year-over-year increase from $192.77 million [2] - Over the last four quarters, Oddity Tech has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - Oddity Tech shares have increased approximately 70.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 6.1% [3] Future Outlook - The company's earnings outlook will be crucial for assessing future stock performance, with current consensus EPS estimates at $0.32 for the coming quarter and $2.04 for the current fiscal year [7] - The Zacks Rank for Oddity Tech is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Internet - Software industry, to which Oddity Tech belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Core Insights - ODDITY Tech Ltd. reported strong financial results for Q2 2025, exceeding guidance across revenue, profit, and earnings per share, indicating robust business growth and profitability [2][4][6] - The company is expanding into new markets, particularly in healthcare with the upcoming launch of Brand 3, which focuses on medical-grade products [3][4] - ODDITY raised its full-year financial outlook for 2025, reflecting confidence in continued growth driven by a backlog of repeat orders [4][9] Financial Performance - Q2 2025 net revenue reached $241 million, a 25% increase year-over-year from $193 million in Q2 2024 [4][6] - Adjusted EBITDA for Q2 2025 was $70 million, up 12% from $62 million in Q2 2024, with an adjusted EBITDA margin of 28.8% [4][6] - Net income for Q2 2025 was $49 million, compared to $45 million in Q2 2024, with a net income margin of 20.4% [4][6] Financial Outlook - The updated full-year 2025 outlook includes net revenue between $799 million and $804 million, representing year-over-year growth of 23% to 24% [9][10] - For Q3 2025, ODDITY expects net revenue between $144 million and $146 million, with a gross margin of approximately 68% [11][9] - Adjusted diluted EPS for the full year is projected to be between $2.06 and $2.09, an increase from the previous outlook [9][10] Strategic Initiatives - The company is progressing towards the formal launch of Brand 3 in Q4 2025 and Brand 4 in 2026, indicating a focus on innovation and market expansion [5][4] - ODDITY is also developing its ODDITY LABS molecule discovery platform, which may enhance its product offerings in the future [5][4] - The company completed its first exchangeable note offering, upsized to $600 million, strengthening its cash position [5][4]